Which demonstrated favourable tolerability and safety profiles.
AFFiRiS reports encouraging outcomes from clinical studies of its two Alzheimer’s vaccines AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer’s vaccines AD01 and AD02, which demonstrated favourable tolerability and safety profiles. These total results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals. All 48 individuals treated in these studies were given four vaccinations that have been well tolerated and no serious side effects linked to the vaccine applicants were observed. The outcomes demonstrate the potential worth of the AFFITOME technology, which forms the platform for both of these vaccines and could result in a generation of highly specific vaccines.Moreover, it is a useful classification with regards to the sample size necessary for vaccine trials. For this reason smaller sized sample size relatively, however, the amount of children in the analysis who acquired lower respiratory tract illness was small . In conclusion, the QIV was been shown to be efficacious in preventing influenza A and B in children 3 to 8 years of age. Given the nagging problem of poor vaccine efficacy against mismatched B lineages, the QIV will end up being of greatest value during seasons in which both lineages are circulating or in the event that there can be an unexpected shift from one lineage to some other.